With cash rapidly running out, the UK's Midatech Pharma PLC hopes to have secured its future by merging with Bioasis Technologies, Inc. to create "a multi-asset rare and orphan disease company" that will be renamed Biodexa Pharmaceuticals.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?